ReNEW: A Phase 3, Double-Masked, Placebo-Controlled Clinical Trial to Evaluate the Efficacy, Safety, and Pharmacokinetics of Subcutaneous Injections of Elamipretide in Subjects Who Have Dry Age-Related Macular Degeneration (Dry AMD)

The goal of this clinical trial is to evaluate the efficacy, safety and pharmacokinetics of elamipretide in subjects with dry age-related macular degeneration (AMD). The main questions it aims to answer are: what is the rate of change in the macular area of photoreceptor loss in subjects who receive a daily dose of elamipretide compared with those who receive a look-alike substance that contains no active drug, and what is the safety and tolerability of elamipretide daily subcutaneous injections. Participants will receive either once daily subcutaneous doses of 40mg elamipretide or placebo and the two treatment groups will be compared.

Start Date30 May 2024

Sponsor / Collaborator

Stealth BioTherapeutics, Inc.

NCT05162768

/ Active, not recruitingPhase 3

A Phase 3 Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of Daily Subcutaneous Injections of Elamipretide in Subjects With Primary Mitochondrial Disease Resulting From Pathogenic Nuclear DNA Mutations (nPMD) NuPower

SPIMD-301 is a 48-week, randomized, double-blind, parallel-group, placebo-controlled trial to assess efficacy and safety of single daily subcutaneous (SC) administration of elamipretide as a treatment for subjects with primary mitochondrial myopathy associated with nuclear DNA mutations (nPMD).

Start Date29 Apr 2022

Sponsor / Collaborator

Stealth BioTherapeutics, Inc.

NCT05168774

/ CompletedPhase 1/2

A Pilot Investigator Initiated Study to Evaluate the Safety, Tolerability and Efficacy of Elamipretide in the Treatment of Advanced Symptoms of Friedreich Ataxia (FRDA)

To evaluate the safety, tolerability, and activity of Elamipretide in treating vision loss in Friedreich Ataxia (FRDA).

Start Date03 Mar 2022

Sponsor / Collaborator

The Children's Hospital of Philadelphia

[+2]

100 Clinical Results associated with Elamipretide Hydrochloride

100 Translational Medicine associated with Elamipretide Hydrochloride

100 Patents (Medical) associated with Elamipretide Hydrochloride

404

Literatures (Medical) associated with Elamipretide Hydrochloride

01 Jun 2025·Biomaterials

A multifunctional mitochondria-protective gene delivery platform promote intervertebral disc regeneration

Article

Author: Wang, Yunbing ; Guo, Chuan ; Zheng, Cheng ; Zhang, Fanjun ; Wu, Ye ; Hu, Cheng ; Zhang, Bo ; Deng, Mingyan ; Kong, Qingquan ; Wang, Yu

Intervertebral disc degeneration (IDD) is a deleterious condition driven by localized inflammation and the associated disruption of the normal homeostatic balance between anabolism and catabolism, contributing to progressive functional abnormalities within the nucleus pulposus (NP). Despite our prior evidence demonstrating that a miR-21 inhibitor can have regenerative effects that counteract the progression of IDD, its application for IDD treatment remains limited by the inadequacy of current local delivery systems. Here, an injectable tannic acid (TA)-loaded hydrogel gene delivery system was developed and used for the encapsulation of a multifunctional mitochondria-protecting gene nanocarrier (PHs). This engineered platform was designed for the sustained on-demand delivery of both miR-21 inhibitor and ss-31 (mitochondrial-targeted peptide) constructs to the NP. This prepared hydrogel could be implanted into the intervertebral disc using a minimally invasive approach whereupon it was able to rapidly release TA. Sustained PHs release was then achieved as appropriate through a mechanism mediated by the activity of MMP-2. Following the targeted uptake of PHs by degenerated NP cells, the subsequent release of encapsulated miR-21 inhibitor suppressed apoptotic cell death and modulated the metabolism of the extracellular matrix (ECM) by targeting the Spry1 gene. At the same time, ss-31 was able to target damaged mitochondria and alleviate inflammatory activity via the suppression of mitochondrial ROS-NLRP3-IL-1β/Caspase1 pathway activity. Synergistic ECM regeneration and anti-inflammatory effects were sufficient to provide therapeutic benefits in an in vivo model of IDD. Together, these results thus highlight this hydrogel-based gene delivery platform as a promising novel approach to the treatment of IDD.

01 Mar 2025·Journal of Lipid Research

Cadmium-cardiolipin disruption of respirasome assembly and redox balance through mitochondrial membrane rigidification

Article

Author: Persicke, Marcus ; Hebrok, Daniel ; Romanova, Nadiya ; Sule, Kevin ; Thévenod, Frank ; Issler, Travis ; Prenner, Elmar J ; Lee, Wing-Kee

The environmental pollutant cadmium (Cd) poses a threat to human health through consumption of contaminated foodstuffs culminating in chronic nephrotoxicity. Mitochondrial dysfunction and excessive reactive oxygen species (ROS) are key to Cd cellular toxicity. Cd-lipid interactions have been less considered. We hypothesized Cd binding to the inner mitochondrial membrane (IMM) phospholipid cardiolipin (CL) and membrane rigidification underlies defective electron transfer by disrupted respiratory supercomplexes (SCs). In Cd-treated rat kidney cortex (rKC) mitoplasts, laurdan (lipid-water interface) and diphenylhexatriene (hydrophobic core) revealed increased and decreased membrane fluidity, respectively. Laurdan-loaded pure CL or IMM biomimetic (40mol% POPC, 35mol% DOPE, 20mol% TOCL, 5mol% SAPI) nanoliposomes were rigidified by 25μM Cd, which was confirmed in live-cell imaging of laurdan or di-4-ANEPPDHQ loaded human proximal convoluted tubule (HPCT) cells. Blue native gel electrophoresis evidenced ∼30% loss of I+III₂+IV_n SC formation after 5μM Cd for 6h in HPCTs, which was reversed by CL-binding drug MTP-131/SS-31/elamipretide (0.1μM), yet α-tocopherol-insensitive. Moreover, MTP131 attenuated Cd-induced H₂O₂ (∼30%) and cytochrome c release (∼25%), but not osmotic swelling, in rKC mitochondria as well as Cd-induced ROS (∼25%) in HPCTs. MTP-131 binding to IMM biomimetic nanoliposomes decreased zeta potential, prevented Cd-induced liposome size increase, and membrane rigidification reported by laurdan. Heterologous CRLS1 expression reversed Cd (5μM, 24h) cytotoxicity (∼25%) by MTT assay, Cd (5μM, 3h)-induced ROS and mitochondrial membrane rigidification by Cd (1μM, 1h) in HPCT cells. In summary, we report a novel mechanism for Cd toxicity in which Cd-CL interactions cause IMM rigidification, thereby disrupting correct SC assembly and increasing ROS.

01 Mar 2025·Advanced Healthcare Materials

Acid‐Triggered Cascaded Responsive Supramolecular Peptide Alleviates Myocardial Ischemia‒Reperfusion Injury by Restoring Redox Homeostasis and Protecting Mitochondrial Function

Article

Author: Mo, Hongwei ; Yang, Pingzhen ; Li, Hekai ; Que, Dongdong ; Song, Xudong ; Liao, Xu ; Cai, Yanbin ; Tang, Min ; Zhang, Xuwei ; Zhong, Chongbin ; Li, Jiejing ; Chen, Xiangzhou ; Yu, Wenjie ; Guo, Runze

AbstractRedox imbalance, including excessive production of reactive oxygen species (ROS) caused by mitochondrial dysfunction and insufficient endogenous antioxidant capacity, is the primary cause of myocardial ischemia‒reperfusion (I/R) injury. In the exploration of reducing myocardial I/R injury, it is found that protecting myocardial mitochondrial function after reperfusion not only reduces ROS bursts but also inhibits cell apoptosis triggered by the release of cytochrome c. Additionally, nuclear factor erythroid 2‐related factor 2 (Nrf2) is considered a potential therapeutic target for treating myocardial I/R injury by enhancing the cellular antioxidant capacity through the induction of endogenous antioxidant enzymes. In this study, a peptide‒drug conjugate OI‐FFG‐ss‐SS31(ISP) is developed by integrating the Nrf2 activator 4‐octyl itaconate (OI) and the mitochondria‐targeting protective peptide elamipretide (SS31), and its therapeutic potential for myocardial I/R injury is explored. The results showed that ISP could self‐assemble into nanofibers in response to the acidic microenvironment and bind to Keap‐1 with high affinity, thereby activating Nrf2 and enhancing antioxidant capacity. Simultaneously, the release of SS31 could improve mitochondrial function and reduce ROS, ultimately providing a restoration of redox homeostasis to effectively alleviate myocardial I/R injury. This study presents a promising acid‐triggered peptide‐drug conjugate for treating myocardial I/R injury.

News (Medical) associated with Elamipretide Hydrochloride

13 Mar 2025

·www.prnewswire.com

Stealth BioTherapeutics Announces Achievement of 50% Enrollment Target in Phase 3 ReNEW Study of Elamipretide in Patients with Dry Age-Related Macular Degeneration

NEEDHAM, Mass., March 13, 2025 /PRNewswire/ -- Stealth BioTherapeutics Inc. (the "Company" or "Stealth"), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapies for diseases involving mitochondrial dysfunction, today announced that it has achieved its 50 percent enrollment target in the global Phase 3 ReNEW study (NCT06373731) of elamipretide in patients with dry age-related macular degeneration (dry AMD). The total target enrollment is 360 participants. The ReNEW study is evaluating the efficacy, safety, and pharmacokinetics of daily subcutaneous injections of elamipretide – a first-in-class mitochondria-targeted investigational therapeutic – in participants with dry AMD. The primary efficacy endpoint (as agreed with the FDA) will measure the rate of change in the macular area of photoreceptor loss, assessed by spectral domain-optical coherence tomography (SD-OCT) and ellipsoid zone (EZ) mapping. Photoreceptors are specialized light-detecting cells in the retina that enable vision in both bright and dim light conditions, and loss of these cells is closely associated with worsening visual function. "Dry AMD, and its late-stage manifestation geographic atrophy, is a devastating disease process that leads to progressive visual dysfunction and irreversible vision loss. Our patients are in need of new and improved treatment options," said Charles Wykoff, MD, PhD from Retinal Consultants of Texas, and Stealth's ReNEW Trial Scientific Review Committee Chair. "A consistent and early hallmark of dry AMD is progressive thinning of the photoreceptors. It is exciting to consider the potential of elamipretide – the first mitochondria-targeted investigational therapy for dry AMD – to slow photoreceptor thinning and loss." "The rapid enrollment of the pivotal Phase 3 ReNEW study underscores this community's desire for novel therapeutics that can be self-administered at home and offer the potential to improve visual function," said Reenie McCarthy, Chief Executive Officer of Stealth. "By targeting retinal bioenergetics to reduce the loss of photoreceptors, we hope to disrupt the progressive vision loss that characterizes this devastating disease." In addition to the ReNEW study, Stealth will initiate the ReGAIN study – a second global Phase 3 trial in dry AMD – in the coming months. Data from the ReNEW study is expected to be reported in 2026. About ReNEW and ReGAIN ReNEW and ReGAIN are Phase 3 global clinical trials evaluating the efficacy and safety of once-daily self-administered subcutaneous injections of elamipretide in participants with dry AMD. The primary endpoint for the trials is the rate of change in the macular area of photoreceptor loss assessed by spectral domain-optical coherence tomography and ellipsoid zone mapping at week 48. In the ReNEW and ReGAIN trials, 360 patients will be randomized 2:1 to either elamipretide or placebo for 96 weeks with the option for participants to enroll in the open-label extension trial, ReTAIN. Learn more about the studies at Dry-AMDClinicalTrials.com. About Dry AMD AMD is the leading cause of irreversible blindness and is estimated by the Vision and Eye Health Surveillance System to affect 19.8 million Americans aged 40 and older (Rein 2022), with 85% to 90% of cases being dry AMD (Schultz 2021). Dry AMD is a progressive retinal disease in which the photoreceptors, which are specialized neurons found in the retina that convert light into electrical signals required for normal visual function, suffer progressive damage and death, leading to loss of vision. Mitochondrial dysfunction, which has been associated with aging, smoking, obesity, and cardiovascular health, is known to precede clinical symptoms of AMD and increase commensurate with AMD disease progression (Feher 2006; Karunadharma 2010; Terluk 2015). Photoreceptor loss can be quantified by measuring the thickness between the EZ and retinal pigment epithelium (i.e., EZ-RPE thickness). Loss of photoreceptors cells, or EZ attenuation, has been shown to precede and predict the loss of visual function and areas of geographic atrophy in dry AMD. About Stealth BioTherapeutics Stealth BioTherapeutics is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel therapies for age-related and rare genetic diseases involving mitochondrial dysfunction. The Company is conducting Phase 3 clinical trials of elamipretide, its lead investigational product candidate, in dry age-related macular degeneration. Elamipretide is also being tested in a fully enrolled Phase 3 clinical trial in primary mitochondrial myopathy, a rare skeletal myopathic disease, and is under review by the Food and Drug Administration for Barth syndrome, an ultra-rare cardioskeletal disease. The Company is developing its second-generation clinical-stage candidate, bevemipretide (SBT-272), for ophthalmic and neurological disease indications. The Company has a deep pipeline of novel mitochondria-targeted compounds under evaluation as therapeutic product candidates. Investor Contact Austin Murtagh Precision AQ [email protected] Media Contact Anna Stallmann Anna Stallmann Communications [email protected] SOURCE Stealth BioTherapeutics Inc. WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

Phase 3

24 Jan 2025

·www.biopharmadive.com

Mixed results for Keytruda; AbbVie to work with Neomorph

Today, a brief rundown of news involving Merck & Co. and AstraZeneca, as well as updates from AbbVie, Stealth BioTherapeutics and Vigil Neuroscience that you may have missed.A regimen of cancer drugs Keytruda and Lenvima extended progression-free survival over standard chemotherapy in people with a type of gastroesophageal tumor, but did not show an overall survival benefit. The results, announced by Merck & Co. and Eisai Friday, are from a Phase 3 study called LEAP-015 that enrolled hundreds of people with locally advanced unresectable or metastatic HER2-negative gastroesophageal adenocarcinoma. The companies said they are continuing to evaluate the data, which theyll present at a future medical meeting. The findings do not affect Keytruda or Lenvimas current approvals, or other trials in the LEAP program. Ned PagliaruloAstraZeneca will invest $570 million in a new office facility in Ontario that will help grow the companys presence in Canada. The drugmaker already employs more than 2,100 people in Canada many of whom work on clinical trials and last year acquired Hamilton, Ontario-based Fusion Pharmaceuticals. The new facility will add more than 700 positions to its workforce there, across all areas of the business, AstraZeneca said Thursday. Ben FidlerAbbVie will work with San Diego-based biotech startup Neomorph to develop protein-degrading molecular glue drugs for cancer and immune diseases, the companies announced Thursday. Neomorph will get an unspecified upfront payment from AbbVie in the deal and stands to receive up to $1.64 billion more in option fees and milestones. Its the third industry collaboration since last February for Neomorph, which also has partnerships with Biogen and Novo Nordisk. Ben FidlerThe Food and Drug Administration will take another three months to decide whether it will approve Stealth BioTherapeutics drug elamipretide for Barth syndrome. The company on Thursday said the FDA determined it needs more time to review recent information submitted by Stealth following an October meeting of agency advisers. The FDA didnt cite any safety issues, nor did it request more testing, Stealth said. The new decision deadline is April 29. Ned PagliaruloShares in Vigil Neuroscience rose by double digits this week after the biotechnology company reported Phase 1 trial data for an experimental drug its developing for Alzheimers. The data, which detail the drugs safety and distribution through the body, support advancement into a Phase 2 study, Vigil said. Code-named VG-3927, the small molecule drug is designed to boost a neuroprotective response in the brain to accumulations of tau and amyloid, proteins associated with Alzheimers. Ned Pagliarulo '

Clinical ResultPhase 1AcquisitionPhase 3Phase 2

24 Jan 2025

·www.pharmaceutical-technology.com

Stealth faces another hurdle as FDA delays decision on Barth syndrome drug

The new PDUFA action date for elamipretide is 29 April 2025. Credit: Fahmi Ruddin Hidayat via Getty Images. The US Food and Drug Administration (FDA) has delayed its decision on Stealth BioTherapeutics ’ new drug application (NDA) for elamipretide, a treatment for the ultra-rare disease Barth syndrome. The Prescription Drug User Fee Act (PDUFA) action date has been extended by three months to 29 April 2025, following the submission of additional information by Stealth. Stealth stated that the FDA required more time to fully review the supplemental data, which was submitted in response to requests following the FDA’s Cardiovascular and Renal Drugs Advisory Committee (CRDAC) meeting in October 2024. At that meeting, the advisory panel voted 10-6 in favour of elamipretide’s approval. The FDA classified the new data as a major amendment to the NDA, which triggered the standard three-month extension. Despite the delay, Stealth emphasised that the FDA has not raised any safety concerns or requested additional pre-market studies. In the announcement accompanying the extension, Stealth’s CEO Reenie McCarthy said: “We continue to work closely with the agency as it completes its review of the elamipretide NDA and are actively preparing to support broad access to this therapy for individuals living with Barth syndrome as quickly as possible following potential approval.” It’s not the first time elamipretide’s development has faced regulatory challenges. The FDA rejected the company’s initial NDA in 2021, citing the lack of “an adequate and well-controlled trial that provides evidence of effectiveness”. That application was based on the SPIBA-001 study (NCT04689360), a Phase III trial incorporating data from prior studies and historical controls. The FDA expressed concerns about potential biases in the trial design, including selection bias and confounding bias, and questioned the methods used to analyse the results. Specifically, the trial compared data from a natural history cohort monitored in 2012 and 2019 with data from treated patients, which the FDA argued did not sufficiently address these biases. The October 2024 AdCom meeting also faced difficulties. The panel discussed findings from the SPIBA-201 clinical trial (NCT03098797), which assessed the impact of elamipretide in 12 male patients over 12 weeks of daily treatment. The trial failed to meet the primary endpoint of improving walking distance. Despite not meeting the efficacy endpoint, patients and physicians have strongly advocated for the drug’s approval. During the AdCom meeting, testimonials highlighted the drug’s positive effects on weight gain, strength, and overall quality of life (QoL) for individuals with Barth syndrome. Jacob Wilson, a 24-year-old male with Barth syndrome told the panel the medicine “made him feel like a new person”. Ultimately, the committee decided to vote in favour of the drug, acknowledging “the devastating impact of Barth’s” and “the significant unmet medical need” in a document released in advance of the AdCom meeting. The life-threatening disease – which causes symptoms such as cardiomyopathy and growth delays – has no cure, and no other therapies in late-stage clinical development, according to the Barth syndrome Foundation.

Phase 3NDA

100 Deals associated with Elamipretide Hydrochloride

External Link

KEGG	Wiki	ATC	Drug Bank
D10925	-	-	DB11981

R&D Status

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Barth Syndrome	NDA/BLA	United States	Stealth BioTherapeutics, Inc.	08 Apr 2024
Mitochondrial Complex I Deficiency	Phase 3	Italy	Stealth BioTherapeutics, Inc.	29 Apr 2022
Mitochondrial Complex I Deficiency	Phase 3	United States	Stealth BioTherapeutics, Inc.	29 Apr 2022
Mitochondrial Myopathies	Phase 3	United Kingdom	Stealth BioTherapeutics, Inc.	09 Oct 2017
Mitochondrial Myopathies	Phase 3	Germany	Stealth BioTherapeutics, Inc.	09 Oct 2017
Mitochondrial Myopathies	Phase 3	United States	Stealth BioTherapeutics, Inc.	09 Oct 2017
Mitochondrial Myopathies	Phase 3	Hungary	Stealth BioTherapeutics, Inc.	09 Oct 2017
Mitochondrial Myopathies	Phase 3	Italy	Stealth BioTherapeutics, Inc.	09 Oct 2017
Mitochondrial Myopathies	Phase 2	Canada	Stealth BioTherapeutics, Inc.	09 Oct 2017
Mitochondrial Myopathies	Phase 2	Denmark	Stealth BioTherapeutics, Inc.	09 Oct 2017

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT03891875 (ReCLAIM-2, Pubmed \| Ophthalmol Sci)	Phase 2	Age Related Macular Degeneration \| Geographic Atrophy \| Visual Acuity	176	Elamipretide 40 mg	gobaohkrvi(puzoxggmqn) = 86% of those receiving elamipretide and 71% of the placebo group with the most common events being injection site reactions (e.g., pruritus, injection site pain, bruising, and erythema) xekybuibrm (hmcaryxkpj ) View more	Positive	01 Jan 2025
				Placebo
NCT03323749 (MMPOWER-3, Pubmed \| Orphanet J Rare Dis)	Phase 3	Mitochondrial Myopathies mtDNA pathogenic variants \| MT-TL1 pathogenic variants \| POLG ... View more	-	Elamipretide	(eljjgapctm) = pcqhwvuimx rjhmjptrka (xnhfccgazf, 8.7)	Positive	21 Nov 2024
				Placebo	(eljjgapctm) = rihzfgfmxi rjhmjptrka (xnhfccgazf, 8.6)
NCT03891875 (ReCLAIM-2, EURETINA2024) Manual	Phase 2	dry age-related macular degeneration	-	Elamipretide (lowest quartile group)	jhnvwxwvzd(uibckmrdzp) = szdhsedkny hquyvsblnw (isxncpkozx ) View more	Positive	19 Sep 2024
				Placebo (lowest quartile group)	jhnvwxwvzd(uibckmrdzp) = swtpglaktk hquyvsblnw (isxncpkozx ) View more
NCT03891875 (RECLAIM-2, CTgov)	Phase 2	Age Related Macular Degeneration \| Geographic Atrophy \| Glycogen Storage Disease Type II	176	Subcutaneous elamipretide through the elamipretide delivery system (Elamipretide)	bxnljbhgih(abzolxqaro) = hgefntxavk fktqoxkghf (rpmjbtdafd, hryndzypmr - yxcdtzkehi) View more	-	17 Oct 2023
				Subcutaneos placebo through the elamipretide delivery system (Placebo)	bxnljbhgih(abzolxqaro) = fogblytqgv fktqoxkghf (rpmjbtdafd, yacsjookzg - kzmfhlmdpm) View more
NCT03323749 (MMPOWER-3, Pubmed)	Phase 3	Mitochondrial Myopathies	218	Elamipretide 40mg/day	cnirprjmze(vdfrpgdppo) = prnbdiaxdv qrbhumuvig (xxlntxtexz )	Negative	02 Jun 2023
NCT03891875 (ReCLAIM-2, ARVO2023)	Phase 2	Geographic Atrophy	117	Elamipretide 40 mg once daily	(lpcqcaokzg) = nrkjzytizv pvoodxmqvd (yzxlotbkhk ) View more	-	23 Apr 2023
				Placebo	(lpcqcaokzg) = lwknbdbntl pvoodxmqvd (yzxlotbkhk ) View more
NCT03891875 (RECLAIM-2, PRNewswire) Manual	Phase 2	Geographic Atrophy	176	ELAMIPRETIDE	uldssfrbol(dwjveblhgh) = guxgfjlzqd cvfpajjvtq (xpugxrkdbn )	Positive	02 May 2022
				Placebo	-
ReCLAIM-1 (AAO2021)	Phase 1	Geographic Atrophy	-	Elamipretide 40mg	(hckzlccjgd) = paumijiium dmcbndxcgo (iuqdqrkmjf ) View more	-	13 Nov 2021
NCT03098797 (Pubmed \| Genet Med) Manual	Phase 2/3	Barth Syndrome	12	elamipretide	(qmijpibart) = ucnepkfitg kzeygshgxk (pduedredsl ) View more	Positive	01 Mar 2021
NCT01755858 (EVOLVE, CTgov)	Phase 1/2	Hypertension, Renovascular \| Renal Artery Obstruction \| Reperfusion Injury	16	Bendavia (Bendavia)	eglooeiyix(qxnyddgnrd) = vvrekhjeya mrqlbfvqye (rudswktixo, ojxsyweley - fjrjehxmyw) View more	-	11 Aug 2020
				Placebo (Placebo)	eglooeiyix(qxnyddgnrd) = llklxcrcaa mrqlbfvqye (rudswktixo, njxdmphqgw - qvorllbqdg) View more

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis